The Combitest® is a prenatal screening test. In other words, it lets you know whether you are at risk of carrying a fetus that may be affected by one of the most common birth defects: trisomy 21, trisomy 18, spina bifida and anencephaly. Furthermore, thanks to high-performance cutting-edge technology, this test is also able to detect other pregnancy-related problems such as preclampsia, for instance.
Quick and simple, the Combitest® is intended for pregnant women of all ages, and can be performed during the first and/or second trimesters of pregnancy.
When the Combitest® is performed between the 11th and 14th week of pregnancy (in the first trimester), it consists of taking a blood sample for analysis and performing a nuchal translucency ultrasound. The reliability of the test results is higher than average with a detection rate greater than 95% and a false positives rate of less than 2%.
In the second trimester (between the 14th and 18th week of pregnancy), the Combitest® requires only that a blood sample be taken for a blood test.
The Combitest® does not pose any danger to the mother or to the fetus, and results are available within 1 to 2 working days after reception of the samples at our laboratories in Montreal.
It is important to remind you that the Combitest® is a screening test and is not meant to give a definitive diagnosis on the state of the fetus that you are carrying. The test results, sent to your treating physician, will show your level of risk of carrying a fetus affected by one of the most common birth defects.
The Combitest® is intended for all pregnant women in their 1st trimester of pregnancy as well as for a large number of women in their 2nd trimester of pregnancy, specifically:
